Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 12/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893695 | 0.92 | THRA (0.51) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL9946067 | 0.88 | MAOB (0.45) | THRATHRBMAOBIDO1AGXT | |
| SCHEMBL9946036 | 0.85 | ESR1 (0.49) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL9946066 | 0.84 | THRA (0.51) | THRATHRBMAOBAGXTPARP10 | |
| SCHEMBL12440978 | 0.81 | THRA (0.56) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL9893782 | 0.81 | MAOB (0.48) | THRATHRBMAOBIDO1AGXT | |
| SCHEMBL9946068 | 0.81 | THRB (0.42) | THRATHRBMAOBMAOAFFAR1 | |
| SCHEMBL3317609 | 0.80 | LIPE (0.50) | THRATHRBMAOB | |
| SCHEMBL9893995 | 0.80 | MAOB (0.51) | THRATHRBESR1NR3C1PGR | |
| SCHEMBL9893602 | 0.80 | ENPP2 (0.56) | THRATHRBESR1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | THRA 1584/4885THRB 898/4885ESR1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.